文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

NK Cell-Based Immunotherapy in Cancer Metastasis.

作者信息

Lorenzo-Herrero Seila, López-Soto Alejandro, Sordo-Bahamonde Christian, Gonzalez-Rodriguez Ana P, Vitale Massimo, Gonzalez Segundo

机构信息

Department of Functional Biology, Immunology, University of Oviedo, 33006 Oviedo, Spain.

Instituto Universitario de Oncología del Principado de Asturias, IUOPA, 33006 Oviedo, Spain.

出版信息

Cancers (Basel). 2018 Dec 28;11(1):29. doi: 10.3390/cancers11010029.


DOI:10.3390/cancers11010029
PMID:30597841
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6357056/
Abstract

Metastasis represents the leading cause of cancer-related death mainly owing to the limited efficacy of current anticancer therapies on advanced malignancies. Although immunotherapy is rendering promising results in the treatment of cancer, many adverse events and factors hampering therapeutic efficacy, especially in solid tumors and metastases, still need to be solved. Moreover, immunotherapeutic strategies have mainly focused on modulating the activity of T cells, while Natural Killer (NK) cells have only recently been taken into consideration. NK cells represent an attractive target for cancer immunotherapy owing to their innate capacity to eliminate malignant tumors in a non-Major Histocompatibility Complex (MHC) and non-tumor antigen-restricted manner. In this review, we analyze the mechanisms and efficacy of NK cells in the control of metastasis and we detail the immunosubversive strategies developed by metastatic cells to evade NK cell-mediated immunosurveillance. We also share current and cutting-edge clinical approaches aimed at unleashing the full anti-metastatic potential of NK cells, including the adoptive transfer of NK cells, boosting of NK cell activity, redirecting NK cell activity against metastatic cells and the release of evasion mechanisms dampening NK cell immunosurveillance.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a072/6357056/525cd0c4099f/cancers-11-00029-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a072/6357056/525cd0c4099f/cancers-11-00029-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a072/6357056/525cd0c4099f/cancers-11-00029-g001.jpg

相似文献

[1]
NK Cell-Based Immunotherapy in Cancer Metastasis.

Cancers (Basel). 2018-12-28

[2]
Mechanisms of Resistance to NK Cell Immunotherapy.

Cancers (Basel). 2020-4-7

[3]
Reformation in chimeric antigen receptor based cancer immunotherapy: Redirecting natural killer cell.

Biochim Biophys Acta Rev Cancer. 2018-1-31

[4]
Cancer Immunotherapy Based on Natural Killer Cells: Current Progress and New Opportunities.

Front Immunol. 2019-5-31

[5]
NK Cells in the Treatment of Hematological Malignancies.

J Clin Med. 2019-9-27

[6]
Driving natural killer cell-based cancer immunotherapy for cancer treatment: An arduous journey to promising ground.

Biomed Pharmacother. 2023-9

[7]
Killers 2.0: NK cell therapies at the forefront of cancer control.

J Clin Invest. 2019-9-3

[8]
NK cell receptors in anti-tumor and healthy tissue protection: Mechanisms and therapeutic advances.

Immunol Lett. 2024-12

[9]
Approaches to Enhance Natural Killer Cell-Based Immunotherapy for Pediatric Solid Tumors.

Cancers (Basel). 2021-6-4

[10]
Overcoming Resistance to Natural Killer Cell Based Immunotherapies for Solid Tumors.

Front Oncol. 2019-2-11

引用本文的文献

[1]
Comprehensive Receptor Repertoire and Functional Analysis of Peripheral NK Cells in Soft Tissue Sarcoma Patients.

Cancers (Basel). 2025-7-30

[2]
Natural killer cells: the immune frontline against circulating tumor cells.

J Exp Clin Cancer Res. 2025-4-10

[3]
Advances and potentials in platelet-circulating tumor cell crosstalk.

Am J Cancer Res. 2025-2-15

[4]
CD56 cytokine-induced memory-like NK cells and NK-cell engagers synergize against non-small cell lung cancer cancer-stem cells.

J Immunother Cancer. 2025-2-12

[5]
Lymphocyte subsets in pediatric acute lymphoblastic leukemia and their prognostic value.

Medicine (Baltimore). 2024-11-1

[6]
Profiling Breast Tumor Heterogeneity and Identifying Breast Cancer Subtypes Through Tumor-Associated Immune Cell Signatures and Immuno Nano Sensors.

Small. 2024-12

[7]
Uncovering novel therapeutic targets in glucose, nucleotides and lipids metabolism during cancer and neurological diseases.

Int J Immunopathol Pharmacol. 2024

[8]
Hybrid epithelial-mesenchymal status of lung cancer dictates metastatic success through differential interaction with NK cells.

J Immunother Cancer. 2024-3-7

[9]
Cellular-Membrane-Derived Vesicles for Cancer Immunotherapy.

Pharmaceutics. 2023-12-22

[10]
CAR NK Cell Therapy for the Treatment of Metastatic Melanoma: Potential & Prospects.

Cells. 2023-11-30

本文引用的文献

[1]
Natural killer cells and other innate lymphoid cells in cancer.

Nat Rev Immunol. 2018-11

[2]
Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade.

J Clin Invest. 2018-9-10

[3]
Allogenic Natural Killer Cell Immunotherapy Combined with Irreversible Electroporation for Stage IV Hepatocellular Carcinoma: Survival Outcome.

Cell Physiol Biochem. 2018

[4]
Combined peripheral natural killer cell and circulating tumor cell enumeration enhance prognostic efficiency in patients with metastatic triple-negative breast cancer.

Chin J Cancer Res. 2018-6

[5]
First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia.

Am J Cancer Res. 2018-6-1

[6]
A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments.

Nat Med. 2018-6-25

[7]
Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity.

Nat Immunol. 2018-6-18

[8]
NK-cell Editing Mediates Epithelial-to-Mesenchymal Transition via Phenotypic and Proteomic Changes in Melanoma Cell Lines.

Cancer Res. 2018-5-11

[9]
In situ delivery of allogeneic natural killer cell (NK) combined with Cetuximab in liver metastases of gastrointestinal carcinoma: A phase I clinical trial.

Oncoimmunology. 2018-3-19

[10]
Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell-driven tumor immunity.

Science. 2018-3-30

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索